KBKathy W. Belk

Kathy W. Belk

*This is an algorithmically generated author record based on publicly available information.

Kathy W. Belk has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Maternal Health Outcomes Associated With Syphilis Infection During Pregnancy: Evidence From a Large US All-Payer Hospital-Centered Administrative Database

    by Abayomi Walker, Deborah Kilday, Michael Korvink, Sydney Westfall, Drew Tatum, Richelle Marshall, Ashley Finke, Stephanie Martin, Raymond Perigard, Kathy W Belk, et al.

    Background: Syphilis during pregnancy is associated with preventable maternal and infant harms. As syphilis rates rise in the United States, recent, nationally representative data on maternal outcomes remain limited. Methods: A retrospective cohort study was conducted using a large all-payer administrative database to assess the prevalence of maternal syphilis, variation in screening, testing, treatment, and associations with maternal outcomes and healthcare utilization. The study included inpatient delivery hospitalizations at 20 or more weeks of gestation discharged 1 October 2019, to 31 December 2023, with 365-day look-back and 90-day follow-up periods. The cohort comprised 3 639 838 deliveries, including 5533 documented with maternal syphilis. Outcomes included hypertensive disorders of pregnancy, severe maternal morbidity (SMM), length of stay, hospital costs, and hospital returns. Results: Syphilis prevalence was 152 per 100 000 deliveries with escalation throughout the study period. Rates were higher among younger, American Indian/Alaska Native and Black, and Medicaid-covered patients. Documented nontreponemal screening and treponemal testing were observed for 29% and 30% of deliveries, respectively. Among deliveries with syphilis, 22% had documented administration of penicillin. After adjustment for maternal and hospital characteristics, syphilis was associated with higher adjusted odds ratio (aOR) of hypertensive disorders (aOR 1.18), 90-day returns (aOR 1.39), SMM including transfusion (aOR 1.23), longer delivery stays (adjusted rate ratio1.09), and higher in-hospital costs (adjusted cost ratio 1.08). Conclusions: Maternal syphilis prevalence increased and was associated with greater maternal morbidity, resource utilization, and costs. Variation in documented screening, testing, and treatment frequencies highlights potential opportunities to improve implementation of recommended care.

  • Open Access

    Mortality and Length of Stay Implications of Deterioration-Associated Transfer to the Intensive Care Unit over Different Time Frames

    by Kathy W Belk, Joseph Beals, Samantha J McInnis

    Background: Quality improvement initiatives in the acute care setting often target reduction of mortality and length of stay (LOS). Unplanned care escalations are associated with increased mortality risk and prolonged LOS, but may be precipitated by different factors, including appropriate triage, bed availability, and post-admission deterioration. Objectives: This work evaluates different transfer timeframes to quantify the impact of deterioration-associated unplanned transfers to intensive care (ICU) on mortality and LOS, informing evidence-based interventions to improve patient care. Design: This retrospective analysis examined 519 181 adult inpatients discharged from 15 hospitals in the United States. A propensity matched cohort analysis compared mortality and overall hospital LOS for patients admitted to routine and intermediate care units who did and did not have an unplanned ICU transfer within 12, 12-48, or ⩾48 hours from admission. Methods: Population cohorts were matched on age, sex, admitting unit type, admission type, and admission acuity. Multivariable regression analysis was used to estimate the impact of unplanned transfer on mortality and LOS. Sensitivity sub-analyses compared direct ICU admissions to unplanned ICU transfers using the same transfer timeframes and endpoints. Results: Patients with unplanned transfers in each of three timeframes had statistically higher mortality rates and longer LOS than matched cohorts without unplanned transfer. Differences between cohorts was greatest in patients transferring ⩾48 hours post-admission for both mortality (25.1% vs 1.9%, P < .0001) and LOS ( x¯ = 14.7 vs 5.3, P < .0001). Multivariate analysis showed unplanned ICU transfer significantly increased odds of mortality and prolonged LOS, with later transfers having the most profound influence (19-fold increase in mortality and 2-fold increase in LOS). Sensitivity analyses found a statistically significant increase in mortality and LOS associated with unplanned ICU transfer across all three timeframes. Conclusion: The association of later transfers with elevated mortality and LOS underscores the importance of timely intervention on patient deterioration.


  • Real World Outcomes Associated with Idarucizumab: Population-Based Retrospective Cohort Study

    by Sonal Singh, Amit Nautiyal, Kathy W. Belk

    Background Idarucizumab reverses the anticoagulant effect of dabigatran, but few comparative studies have reported on clinical outcomes with idarucizumab. Objective Our objective was to determine the effect of idarucizumab on clinical outcomes. Methods We conducted a retrospective cohort study in a nationally representative sample of hospitals in the United States. The study population included adults ≥ 18 years who were hospitalized for dabigatran-associated major bleeding between January 1, 2015 and December 31, 2017. We compared idarucizumab-exposed patients to the unexposed group. Our primary outcome of interest was in-hospital mortality. Results We included 266 exposed and 1345 non-exposed participants across 271 hospitals. Among participants with gastrointestinal bleeding, there was no statistically significant difference in the odds of in-hospital mortality [9/153 (5.9%) vs 37/1124 (3.3%); adjusted odds ratio = 1.39, 95% confidence interval 0.51–3.45] between the idarucizumab-exposed and non-exposed groups. Among participants with intracranial bleeding, there was an excess of in-hospital mortality [13/112 (11.6%) vs 6/217 (2.8%)] associated with idarucizumab exposure, but limitations include sparse data and the inability to rule out residual confounding or confounding by disease severity. Conclusions Among a large nationally representative sample of adult patients with dabigatran-associated major bleeding in the United States, we found no difference in in-hospital mortality among patients with gastrointestinal bleeding associated with idarucizumab exposure. An excess risk of in-hospital mortality associated with idarucizumab exposure among participants with intracranial bleeding deserves further exploration.